Open Access#12013
The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
On May 10, 2012, a conditional marketing authorization valid throughout the European Union was granted for pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. This article summarizes the scientific review of the application leading to approval in the European Union.
